Instituto de Biomedicina de Sevilla -ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2023

  1. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A

    Signal Transduction and Targeted Therapy, Vol. 8, Núm. 1